Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478252 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT05478252 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 388 participants.
The verdict
NCT05478252, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months).
Interventions
- DRUG Semaglutide J
- DRUG Semaglutide B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2023-09-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478252
The ClinicalTrials.gov registry entry for NCT05478252 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide J is the first listed.
NCT05478252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05478252 about?
NCT05478252 is a clinical study titled "A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes". The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need...
What is the current status of trial NCT05478252?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2022-08-03. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT05478252?
The interventions under investigation include: Semaglutide J (DRUG), Semaglutide B (DRUG).
Who is sponsoring clinical trial NCT05478252?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.